Literature DB >> 30740432

Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective.

Olivia McCarthy1,2, Steve C Bain1, Rachel Deere1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30740432      PMCID： PMC6330636          DOI： 10.21037/atm.2018.11.63

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  42 in total

1.  Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro).

Authors:  R Rabasa-Lhoret; J Bourque; F Ducros; J L Chiasson
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

2.  Cellular origin of hexokinase in pancreatic islets.

Authors:  F Schuit; K Moens; H Heimberg; D Pipeleers
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

3.  Glucose response to intense aerobic exercise in type 1 diabetes: maintenance of near euglycemia despite a drastic decrease in insulin dose.

Authors:  Franck Mauvais-Jarvis; Eugène Sobngwi; Raphaël Porcher; Jean Pierre Garnier; Patrick Vexiau; Alain Duvallet; Jean-François Gautier
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

Review 4.  Exercise in the management of type 1 diabetes mellitus.

Authors:  Jeanne H Steppel; Edward S Horton
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 6.514

5.  A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.

Authors:  Johannes Plank; Andrea Wutte; Gernot Brunner; Andrea Siebenhofer; Barbara Semlitsch; Romana Sommer; Sabine Hirschberger; Thomas R Pieber
Journal:  Diabetes Care       Date:  2002-11       Impact factor: 19.112

6.  Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response.

Authors:  Salomon Banarer; Veronica P McGregor; Philip E Cryer
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

7.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Authors:  M Lepore; S Pampanelli; C Fanelli; F Porcellati; L Bartocci; A Di Vincenzo; C Cordoni; E Costa; P Brunetti; G B Bolli
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

8.  Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.

Authors:  G U Kuerzel; U Shukla; H E Scholtz; S G Pretorius; D H Wessels; C Venter; M A Potgieter; A M Lang; T Koose; E Bernhardt
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

9.  Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.

Authors:  Thomas Danne; Reinhard H A Becker; Tim Heise; Claudia Bittner; Annke D Frick; Klaus Rave
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

Review 10.  Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

Authors: 
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112
View more
  1 in total

1.  Automatically accounting for physical activity in insulin dosing for type 1 diabetes.

Authors:  Basak Ozaslan; Stephen D Patek; Chiara Fabris; Marc D Breton
Journal:  Comput Methods Programs Biomed       Date:  2020-09-21       Impact factor: 5.428
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.